{"id":"W2970734757","doi":"10.1158/1078-0432.ccr-18-4121","title":"Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors","year":2019,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":164,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Cancer Research","funders":"National Cancer Institute; Genentech; Pharmacyclics; Eisai; National Institutes of Health; Cancer Research UK; Gilead Sciences; GlaxoSmithKline; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Nausea; Adverse effect; Pharmacokinetics; Response Evaluation Criteria in Solid Tumors; Pharmacodynamics; Regimen; Progressive disease; Internal medicine; Dosing; Gastroenterology; Toxicity; Pharmacology; Chemotherapy; Oncology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008727074,0.0000903894,0.0002819597,0.00004822785,0.00003200147,0.000005444929,0.0002022982,0.0001089322,0.00001300359],"category_scores_gemma":[0.0003023674,0.00005831448,0.00004021634,0.0002126461,0.0002649467,0.000004123886,0.0002372487,0.0002413454,7.406795e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001355328,"about_ca_system_score_gemma":0.000142047,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006067822,"about_ca_topic_score_gemma":0.0001914549,"domain_scores_codex":[0.9984128,0.0002351909,0.0004687972,0.0003555731,0.0003198743,0.0002076979],"domain_scores_gemma":[0.9989333,0.0001179716,0.0001730633,0.0004025564,0.0003201842,0.00005293502],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001297061,0.002542364,0.8478779,0.00004966257,0.00003475539,4.544224e-7,0.0001087453,0.0001024441,0.1441331,0.000006719983,0.000009413998,0.003837411],"study_design_scores_gemma":[0.01163982,0.0118724,0.6841937,0.0001030287,0.00001186261,1.525219e-7,0.0002469998,0.00002811471,0.2915686,0.00005351089,0.0001555099,0.0001263586],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.998345,0.0005681316,0.000009822959,0.00003526497,0.00008960516,0.0008521733,0.00001749425,0.000001294961,0.00008123599],"genre_scores_gemma":[0.9995788,0.0001777578,0.00005806658,0.00001296362,0.00003246865,0.00004661532,0.00000606491,0.0000118867,0.00007536731],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1636842,"threshold_uncertainty_score":0.2377995,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05720851192970894,"score_gpt":0.4582961304115014,"score_spread":0.4010876184817924,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}